Not Signed In - Phase III Pivotal Trial of DB289 To Treat Trypanosomiasis (African sleeping sickness)
Fri, 26 Aug 2005 06:00 AM EST
... ImmtechInternational, Inc (Amex: IMM) announced today that it has initiated, inpartnership with the University of North Carolina at Chapel Hill, a Phase IIIpivotal trial of its oral drug DB289 in the Democratic Republic of Congo totreat Trypanosomiasis (African sleeping sickness) and that it is screeningpatients for enrollment... click link for more info. ...
Related Topics
- African Trypanosomiasis
- Sleeping Sickness
- Clinical Trials
- Trypanosomiasis, African
- Motion Sickness
- African American
- African-American Health
- Antithrombin III
- Chagas Disease
- Trypanosomiasis, American
- Acetazolamide
- Familial Dysautonomia
- African American / Black Women
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Crohn's Disease
- Congenital antithrombin III deficiency
- Cranial mononeuropathy III - compression type
- Cranial mononeuropathy III - diabetic type
- Antithrombin
email this page
print this page
bookmark this page
feedback on this page
